Patents by Inventor Albert Deisseroth

Albert Deisseroth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9757438
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 12, 2017
    Assignee: MICROVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Publication number: 20170014497
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Application
    Filed: July 19, 2016
    Publication date: January 19, 2017
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 9533036
    Abstract: Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and also administering the encoded fusion protein. In another approach, an immune response to the foreign antigen is elicited using the encoded fusion protein without administering the vector. The invention methods may be used to immunize an individual against an infectious agent such as influenza virus. Methods of obtaining an immune response in older individuals also is described.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: January 3, 2017
    Assignee: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 9402920
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: August 2, 2016
    Assignee: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Publication number: 20140322301
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 30, 2014
    Applicant: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 8828957
    Abstract: Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: September 9, 2014
    Assignee: MicroVAX, LLC
    Inventors: Albert Deisseroth, Yucheng Tang, Wei-Wei Zhang, Xiang-Ming Fang
  • Patent number: 8742087
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: June 3, 2014
    Assignee: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Publication number: 20140073045
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Application
    Filed: July 23, 2013
    Publication date: March 13, 2014
    Applicant: MicroVAX, LLC.
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 8501707
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: August 6, 2013
    Assignee: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 8299229
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: October 30, 2012
    Assignee: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 7304092
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus.
    Type: Grant
    Filed: November 11, 2003
    Date of Patent: December 4, 2007
    Assignee: Yale University
    Inventors: David J. Austin, Viet-Ahn A. Nguyen, Doris Pupowicz, Albert Deisseroth, Tao Wang, Enrica Lerma
  • Publication number: 20070269409
    Abstract: Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
    Type: Application
    Filed: November 12, 2003
    Publication date: November 22, 2007
    Inventors: Albert Deisseroth, Lixin Zhang
  • Publication number: 20070128223
    Abstract: Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and also administering the encoded fusion protein. In another approach, an immune response to the foreign antigen is elicited using the encoded fusion protein without administering the vector. The invention methods may be used to immunize an individual against an infectious agent such as influenza virus. Methods of obtaining an immune response in older individuals also is described.
    Type: Application
    Filed: November 6, 2006
    Publication date: June 7, 2007
    Inventors: Yucheng Tang, Albert Deisseroth
  • Publication number: 20060286074
    Abstract: Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and CD40 ligand. In other methods, administration of a fusion protein containing the TVECA and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. Further methods comprise the combination therapy using an expression vector encoding a secretable TVECA fusion protein and a tumor antigen vaccine.
    Type: Application
    Filed: May 26, 2006
    Publication date: December 21, 2006
    Inventors: Yucheng Tang, Albert Deisseroth
  • Publication number: 20050226888
    Abstract: Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.
    Type: Application
    Filed: December 10, 2004
    Publication date: October 13, 2005
    Inventors: Albert Deisseroth, Yucheng Tang, Wei-Wei Zhang, Xiang-Ming Fang
  • Publication number: 20050226887
    Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
    Type: Application
    Filed: November 23, 2004
    Publication date: October 13, 2005
    Inventors: Yucheng Tang, Albert Deisseroth